Activin receptor modulation

Anna Mies, Amit K. Verma, Uwe Platzbecker

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Conventional treatment regimen of lower-risk MDS with erythropoiesis-stimulating agents often fails to induce sustained erythroid improvement in these patients that frequently harbor defects in late-stage erythroblasts downstream of erythropoietin action. Thus, alternative treatment options that would achieve sustainable transfusion independence are needed. In this chapter, we will discuss activin receptor ligand traps as novel therapeutic strategies for low-risk MDS subgroups that were recently shown to alleviate anemia by specifically inhibiting aberrant TGF-β signaling and thereby promoting erythroid differentiation.

Original languageEnglish (US)
Title of host publicationHematologic Malignancies
PublisherSpringer Verlag
Pages97-104
Number of pages8
DOIs
StatePublished - Jan 1 2018

Publication series

NameHematologic Malignancies
ISSN (Print)2197-9766
ISSN (Electronic)2197-9774

Fingerprint

Activin Receptors
Hematinics
Erythroblasts
Erythropoietin
Anemia
Therapeutics
Ligands

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Mies, A., Verma, A. K., & Platzbecker, U. (2018). Activin receptor modulation. In Hematologic Malignancies (pp. 97-104). (Hematologic Malignancies). Springer Verlag. https://doi.org/10.1007/978-3-319-76879-3_7

Activin receptor modulation. / Mies, Anna; Verma, Amit K.; Platzbecker, Uwe.

Hematologic Malignancies. Springer Verlag, 2018. p. 97-104 (Hematologic Malignancies).

Research output: Chapter in Book/Report/Conference proceedingChapter

Mies, A, Verma, AK & Platzbecker, U 2018, Activin receptor modulation. in Hematologic Malignancies. Hematologic Malignancies, Springer Verlag, pp. 97-104. https://doi.org/10.1007/978-3-319-76879-3_7
Mies A, Verma AK, Platzbecker U. Activin receptor modulation. In Hematologic Malignancies. Springer Verlag. 2018. p. 97-104. (Hematologic Malignancies). https://doi.org/10.1007/978-3-319-76879-3_7
Mies, Anna ; Verma, Amit K. ; Platzbecker, Uwe. / Activin receptor modulation. Hematologic Malignancies. Springer Verlag, 2018. pp. 97-104 (Hematologic Malignancies).
@inbook{6a9347cc50cd4b30b4756f9240a9ab6a,
title = "Activin receptor modulation",
abstract = "Conventional treatment regimen of lower-risk MDS with erythropoiesis-stimulating agents often fails to induce sustained erythroid improvement in these patients that frequently harbor defects in late-stage erythroblasts downstream of erythropoietin action. Thus, alternative treatment options that would achieve sustainable transfusion independence are needed. In this chapter, we will discuss activin receptor ligand traps as novel therapeutic strategies for low-risk MDS subgroups that were recently shown to alleviate anemia by specifically inhibiting aberrant TGF-β signaling and thereby promoting erythroid differentiation.",
author = "Anna Mies and Verma, {Amit K.} and Uwe Platzbecker",
year = "2018",
month = "1",
day = "1",
doi = "10.1007/978-3-319-76879-3_7",
language = "English (US)",
series = "Hematologic Malignancies",
publisher = "Springer Verlag",
pages = "97--104",
booktitle = "Hematologic Malignancies",

}

TY - CHAP

T1 - Activin receptor modulation

AU - Mies, Anna

AU - Verma, Amit K.

AU - Platzbecker, Uwe

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Conventional treatment regimen of lower-risk MDS with erythropoiesis-stimulating agents often fails to induce sustained erythroid improvement in these patients that frequently harbor defects in late-stage erythroblasts downstream of erythropoietin action. Thus, alternative treatment options that would achieve sustainable transfusion independence are needed. In this chapter, we will discuss activin receptor ligand traps as novel therapeutic strategies for low-risk MDS subgroups that were recently shown to alleviate anemia by specifically inhibiting aberrant TGF-β signaling and thereby promoting erythroid differentiation.

AB - Conventional treatment regimen of lower-risk MDS with erythropoiesis-stimulating agents often fails to induce sustained erythroid improvement in these patients that frequently harbor defects in late-stage erythroblasts downstream of erythropoietin action. Thus, alternative treatment options that would achieve sustainable transfusion independence are needed. In this chapter, we will discuss activin receptor ligand traps as novel therapeutic strategies for low-risk MDS subgroups that were recently shown to alleviate anemia by specifically inhibiting aberrant TGF-β signaling and thereby promoting erythroid differentiation.

UR - http://www.scopus.com/inward/record.url?scp=85049759919&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049759919&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-76879-3_7

DO - 10.1007/978-3-319-76879-3_7

M3 - Chapter

AN - SCOPUS:85049759919

T3 - Hematologic Malignancies

SP - 97

EP - 104

BT - Hematologic Malignancies

PB - Springer Verlag

ER -